Patient Registries Prove Value As Drug Development Tools

It's easy for pharmaceutical and biotechnology companies to get caught up in biomarkers and scientific clinical endpoints as the end goals in drug development, but a novel, practical approach is gaining momentum: asking the patient what they need or want from new medicines.

More companies are using patient registries or creating their own registries to do more than track side effects after new drugs hit the market. The data are being collected and analyzed to inform development programs, assist in clinical trial design and, increasingly, to show regulators and payers the value of their medicines in the eyes of patients